Similar articles

• Postinterferon α-fetoprotein elevation and risk of hepatocellular carcinoma development after sustained virological response: cause or results?

  Toyoda H, Kumada T, Tada T. Toyoda H, et al. Hepatology. 2014 Aug;60(2):762-3. doi: 10.1002/hep.27064. Epub 2014 Jun 18. Hepatology. 2014. PMID: 24519154 No abstract available.
• Reply: To PMID 23564522.

  Asahina Y, Tsuchiya K, Izumi N. Asahina Y, et al. Hepatology. 2014 Aug;60(2):764. doi: 10.1002/hep.27066. Epub 2014 Jun 18. Hepatology. 2014. PMID: 24519221 No abstract available.
• α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.

  Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nakagawa M, Kakinuma S, Watanabe M, Izumi N. Asahina Y, et al. Hepatology. 2013 Oct;58(4):1253-62. doi: 10.1002/hep.26442. Epub 2013 Aug 19. Hepatology. 2013. PMID: 23564522
• [Effects of IFN therapy on incidence of hepatocellular carcinoma in HCV positive cirrhosis].

  Nishiguchi S, Kubo S, Shiomi S. Nishiguchi S, et al. Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):600-4. Nihon Rinsho. 2004. PMID: 15359868 Review. Japanese. No abstract available.
• [Chronic hepatitis C in hemodialysis patients].

  Tanaka H, Ueda H, Ichinose M, Miyano M. Tanaka H, et al. Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):645-8. Nihon Rinsho. 2004. PMID: 15359877 Review. Japanese. No abstract available.